MedTrace Logo

Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

NCT02967939 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2021-04-14

No results posted yet for this study

Summary

A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic hepatitis B patients

Conditions

  • Hepatitis B， Chronic

Interventions

DRUG

DA-2802

DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.

DRUG

Viread®

Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jong eun Yeon · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-28
Primary Completion
2019-01-23
Completion
2019-07-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02967939 on ClinicalTrials.gov